Myofascial Pain SyndromeNCT06012786
Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
An observational study of Myofascial Pain Syndrome and Breast Cancer, run by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to determine the relationship between Lymphedema and Myofascial Pain Syndrome in Breast Cancer Patients. The main questions it aims to answer: Is there a relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer… Read more about this study
- Who is it for?
- Ages 18 to 75 years, women only
- Conditions the study is for
- Myofascial Pain Syndrome, Breast Cancer, Breast Cancer Female
- What is being tested?
- Diagnostic Criteria of Myofascial Pain Syndrome, The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer and Hand Grip Test
- Type of treatment
- Injection or infusion
- How many people
- 110 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 30 Aug 2023to 20 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Breast Cancer patients aged between 18-75 years old, who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy visiting our oncological rehabilitation outpatient clinic between August 2023 and May 2024.
Who may be able to join
- Breast cancer patients aged between 18-75 who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy providing a written consent to participate in the study
Who cannot join
- Patients who do not agree to participate the study
- Patients who had signs of active infection as lymphangitis, cellulitis, fungus
- Bilateral breast cancer patients
- Uncontrolled Psychiatric illness
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Sultan 2. Abdulhamid Han Training and Research Hospital
Istanbul, Kadıköy, 34668
About this study
The goal of this observational study is to determine the relationship between Lymphedema and Myofascial Pain Syndrome in Breast Cancer Patients.
The main questions it aims to answer:
- Is there a relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients?
- Does the existence of lymphedema in breast cancer patients affect the distribution and the pain threshold values of trigger points seen in Myofascial Pain Syndrome?
- What is the impact of Myofascial pain syndrome seen in breast cancer associted lymhedema patients on upper extremity function and quality of life?
Read the detailed description
Mastectomy, breast conserving surgery, axillary lymph node dissection, sentinel lymph node biopsy and radiotherapy treatments have significant results in skin, muscle and fascia tissues in the upper extremity.
Upper extremity function is defined by the International Consortium for Measures of Health Outcomes (ICHOM) as one of the most important health measures in breast cancer patients. Long-term upper extremity dysfunction has serious effects on patients' quality of life.
Lymphedema, severe pain, decrease in shoulder joint range of motion, myofascial pain syndrome, myofascial adhesions are the leading causes affecting upper extremity function in patients with breast cancer.
Myofascial pain syndrome (MPS) is commonly seen in patients with musculoskeletal problems and originates from muscle and surrounding tissues. It is characterized by localized or referred pain in a limited area and trigger points in the affected muscles. The incidence of myofascial pain syndrome secondary to breast cancer surgery is unknown. There is not yet a study in the literature that reveals the relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients.
This study is designed as cross sectional- single centered and single blind. It is planned to include 110 breast cancer patients who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy aged between 18-75 years-old, visiting our oncological rehabilitation outpatient clinic August 2023 through May 2024.
Patients will be divided into 2 groups according to the stage of lymphedema. It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent) . The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55) Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55) The frequency of myofascial pain syndrome will be determined by the diagnostic criterias in both groups. The trigger points in trapezius, infraspinatus, serratus anterior, latissimus dorsi and pectoralis major muscles will be examined and the pain-pressure threshold values will be measured with an algometer.
For the evaluation of upper extremity function and quality of life following measurement tools will be utilized in both groups: Hand-grip test with a dynamometer, goniometric measurement of range of motion (ROM) of shoulder joint, VAS numerical scales, LYMQOL and DASH questionnaires.
Data analysis will be performed by using the Statistical Package for the Social Sciences (SPSS, version 20.0, IBM Corp., Armonk, NY, USA).
- Conditions
- Myofascial Pain Syndrome, Breast Cancer, Breast Cancer Female, Lymphedema, Lymphedema of Upper Limb, Pain
- Being tested
- Diagnostic Criteria of Myofascial Pain Syndrome, The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer, Hand Grip Test, VAS, Quick DASH
- Keywords
- breast cancer, myofascial pain syndrome, lymphedema
- Medical subject headings
- Myofascial Pain Syndromes, Breast Neoplasms, Lymphedema, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic Criteria of Myofascial Pain SyndromeDiagnostic test
Major criteria:
- The patient's complaint of regional pain
- Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point
- Presence of palpable taut band
- Presence of palpable and tender points along the length of the taut band
- Restriction of ROM in the area of the affected muscle
Minor criteria:
- Pain/sensory change with pressure palpation of the trigger point
- Local twitch response with palpation/injection of the trigger point in the taut band
- Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis
The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an AlgometerDiagnostic test
Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
Hand Grip TestDiagnostic test
The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
VASDiagnostic test
Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Quick DASHDiagnostic test
The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
Lymqol-ArmDiagnostic test
Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
Range of Motion of Shoulde JointDiagnostic test
Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (Patients with Stage 0 lymphedema) | It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent). The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55) Receives: Diagnostic Test: Diagnostic Criteria of Myofascial Pain Syndrome; Diagnostic Test: The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer; Diagnostic Test: Hand Grip Test; Diagnostic Test: VAS; Diagnostic Test: Quick DASH; Diagnostic Test: Lymqol-Arm; Diagnostic Test: Range of Motion of Shoulde Joint | |
| Group 2 (Patients with Stage 1,2 or 3 lymphedema) | Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55) Receives: Diagnostic Test: Diagnostic Criteria of Myofascial Pain Syndrome; Diagnostic Test: The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer; Diagnostic Test: Hand Grip Test; Diagnostic Test: VAS; Diagnostic Test: Quick DASH; Diagnostic Test: Lymqol-Arm; Diagnostic Test: Range of Motion of Shoulde Joint |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Evaluation of Trigger Points
Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
Measured: 3 days
Clinical Diagnostic Criteria of Myofascial Pain Syndrome
Major criteria: 1. The patient's complaint of regional pain 2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point 3. Presence of palpable taut band 4. Presence of palpable and tender points along the length of the taut band 5. Restriction of ROM in the area of the affected muscle Minor criteria: 1. Pain/sensory change with pressure palpation of the trigger point 2. Local twitch response with palpation/injection of the trigger point in the taut band 3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis
Measured: 3 days
Secondary outcomes (5)
Hand Grip Test
The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
Measured: 3 days
Range of motion of shoulder joint
Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
Measured: 3 days
VAS
Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
Measured: 3 days
Quick-DASH (The Disabilities of the Arm, Shoulder and Hand)
The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
Measured: 3 days
LYMQOL-arm (Lymphedema Quality of Life -arm)
Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
Measured: 3 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2023
- Study start30 Aug 2023
- Primary completion30 Aug 2024
- Study completion20 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myofascial Pain SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yeliz Bahar Özdemir, Principal investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06012786
- Sponsor's protocol ID
- 23/338
- Status last verified
- Sep 2025
- First submitted
- 22 Aug 2023
- Last updated
- 12 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
- ClinicalTrials.gov ID
- NCT06012786
- Acronym / sponsor ID
- 23/338
- Conditions
- Myofascial Pain Syndrome, Breast Cancer, Breast Cancer Female, Lymphedema, Lymphedema of Upper Limb, Pain
- Keywords
- breast cancer, myofascial pain syndrome, lymphedema
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyUniversity, hospital or other
- Study start
- 30 Aug 2023 (actual)
- Primary completion
- 30 Aug 2024 (actual)
- Study completion
- 20 Feb 2025 (actual)
- First posted
- 25 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to determine the relationship between Lymphedema and Myofascial Pain Syndrome in Breast Cancer Patients.
The main questions it aims to answer:
- Is there a relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients?
- Does the existence of lymphedema in breast cancer patients affect the distribution and the pain threshold values of trigger points seen in Myofascial Pain Syndrome?
- What is the impact of Myofascial pain syndrome seen in breast cancer associted lymhedema patients on upper extremity function and quality of life?
Detailed description
Mastectomy, breast conserving surgery, axillary lymph node dissection, sentinel lymph node biopsy and radiotherapy treatments have significant results in skin, muscle and fascia tissues in the upper extremity.
Upper extremity function is defined by the International Consortium for Measures of Health Outcomes (ICHOM) as one of the most important health measures in breast cancer patients. Long-term upper extremity dysfunction has serious effects on patients' quality of life.
Lymphedema, severe pain, decrease in shoulder joint range of motion, myofascial pain syndrome, myofascial adhesions are the leading causes affecting upper extremity function in patients with breast cancer.
Myofascial pain syndrome (MPS) is commonly seen in patients with musculoskeletal problems and originates from muscle and surrounding tissues. It is characterized by localized or referred pain in a limited area and trigger points in the affected muscles. The incidence of myofascial pain syndrome secondary to breast cancer surgery is unknown. There is not yet a study in the literature that reveals the relationship between the stage of lymphedema and the frequency of accompanying myofascial pain syndrome in the breast cancer patients.
This study is designed as cross sectional- single centered and single blind. It is planned to include 110 breast cancer patients who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy aged between 18-75 years-old, visiting our oncological rehabilitation outpatient clinic August 2023 through May 2024.
Patients will be divided into 2 groups according to the stage of lymphedema. It is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent) . The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55) Patients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55) The frequency of myofascial pain syndrome will be determined by the diagnostic criterias in both groups. The trigger points in trapezius, infraspinatus, serratus anterior, latissimus dorsi and pectoralis major muscles will be examined and the pain-pressure threshold values will be measured with an algometer.
For the evaluation of upper extremity function and quality of life following measurement tools will be utilized in both groups: Hand-grip test with a dynamometer, goniometric measurement of range of motion (ROM) of shoulder joint, VAS numerical scales, LYMQOL and DASH questionnaires.
Data analysis will be performed by using the Statistical Package for the Social Sciences (SPSS, version 20.0, IBM Corp., Armonk, NY, USA).
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 (Patients with Stage 0 lymphedema) | – | Diagnostic Test: Diagnostic Criteria of Myofascial Pain Syndrome, Diagnostic Test: The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer, Diagnostic Test: Hand Grip Test, Diagnostic Test: VAS, Diagnostic Test: Quick DASH, Diagnostic Test: Lymqol-Arm, Diagnostic Test: Range of Motion of Shoulde JointIt is known that pathophysiological changes develop even if there is no visible lymphedema in patients undergoing surgery and/or radiotherapy for breast cancer. There is a lifetime risk of developing lymphedema, so these patients are considered as Stage 0 (latent). The patients with less than 3 cm difference between the circumference measurements of upper extremities will be included in the 1st group.( Stage 0) (n=55) |
| Group 2 (Patients with Stage 1,2 or 3 lymphedema) | – | Diagnostic Test: Diagnostic Criteria of Myofascial Pain Syndrome, Diagnostic Test: The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer, Diagnostic Test: Hand Grip Test, Diagnostic Test: VAS, Diagnostic Test: Quick DASH, Diagnostic Test: Lymqol-Arm, Diagnostic Test: Range of Motion of Shoulde JointPatients who have more than 3 cm difference between the circumference measurements of upper extremities and those with Stage 1,2 or 3 lymphedema will be included in the second group (n=55) |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Breast Cancer patients aged between 18-75 years old, who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy visiting our oncological rehabilitation outpatient clinic between August 2023 and May 2024.
Key inclusion criteria (1 listed)
- Breast cancer patients aged between 18-75 who had undergone the treatments as mastectomy, breast conserving surgery, lymph node dissection, sentinele lymph node biopsy or radiotherapy providing a written consent to participate in the study
Key exclusion criteria (4 listed)
- Patients who do not agree to participate the study
- Patients who had signs of active infection as lymphangitis, cellulitis, fungus
- Bilateral breast cancer patients
- Uncontrolled Psychiatric illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic Criteria of Myofascial Pain SyndromeMajor criteria: 1. The patient's complaint of regional pain 2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point 3. Presence of palpable taut band 4. Presence of palpable and tender points along the length of the taut band 5. Restriction of ROM in the area of the affected muscle Minor criteria: 1. Pain/sensory change with pressure palpation of the trigger point 2. Local twitch response with palpation/injection of the trigger point in the taut band 3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
| The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an AlgometerTrigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups. | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
| Hand Grip TestThe purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately. | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
| VASShoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale. | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
| Quick DASHThe quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function. | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
| Lymqol-ArmLymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population. | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
| Range of Motion of Shoulde JointGoniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken. | Diagnostic test | Group 1 (Patients with Stage 0 lymphedema), Group 2 (Patients with Stage 1,2 or 3 lymphedema) |
Primary outcome
The Evaluation of Trigger Points
Time frame: 3 days
Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
Clinical Diagnostic Criteria of Myofascial Pain Syndrome
Time frame: 3 days
Major criteria: 1. The patient's complaint of regional pain 2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point 3. Presence of palpable taut band 4. Presence of palpable and tender points along the length of the taut band 5. Restriction of ROM in the area of the affected muscle Minor criteria: 1. Pain/sensory change with pressure palpation of the trigger point 2. Local twitch response with palpation/injection of the trigger point in the taut band 3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis
5 secondary outcomes
Hand Grip Test
Time frame: 3 days
Range of motion of shoulder joint
Time frame: 3 days
VAS
Time frame: 3 days
Quick-DASH (The Disabilities of the Arm, Shoulder and Hand)
Time frame: 3 days
LYMQOL-arm (Lymphedema Quality of Life -arm)
Time frame: 3 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2025.
- Individual participant dataSharing planned: Undecided. Undecided
Related trials for Myofascial Pain Syndrome
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
Not yet recruiting
Effects of IASTM, Deep Friction Massage, and Sham Instrument-Assisted Soft Tissue Mobilization on Electromyographical Activation, Pain and Function in Non-Specific Low Back Pain
Low Back Pain, Trigger Point Pain, Myofascial
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yeliz Bahar Özdemir principal investigator
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myofascial Pain Syndrome and Breast Cancer, run by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Evaluation of Trigger Points (time frame: 3 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2025.